Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza A virus neuraminidase N1 subtype is a viral surface glycoprotein enzyme found on the envelope of influenza A virions. It is a homotetrameric type II membrane protein that cleaves terminal sialic acid residues from glycoproteins and glycolipids on the host cell surface and within respiratory mucus, facilitating virus release and spread following replication. The enzyme's substrate specificity and conserved active site make it a validated target for antiviral drugs, several of which are licensed for influenza treatment. Resistance can arise from mutations in the neuraminidase gene, necessitating ongoing surveillance and novel therapeutic strategies.
Inhibition of neuraminidase catalytic activity by competitive binding to its active site, prevents cleavage of sialic acid and release of new virions from infected cells
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus neuraminidase N1 subtype (N1 neuraminidase).